Results from two studies were presented at the 22nd European Society of Hypertension (ESH) in London highlighting the benefits of triple combination therapy for individuals suffering from hypertension.
The results add to clinical understanding of olmesartan(O)/amlodipine(A)/hydrochlorothiazide(H) (O/A/H) triple combination therapy (Sevikar HCT®).
About 15 to 20% of patients with hypertension are not controlled by dual therapy. Given that many of these patients will subsequently require triple combination therapy, means that further proof of this approach’s efficacy is welcome.
O/A/H is a single pill that contains three anti-hypertensive agents and is indicated for the treatment of individuals with hypertension. The pill contains the following three agents:
- olmesartan medoxomil (OLM) – a long-acting selective angiotensin II receptor blocker
- amlodipine (AML) – a calcium channel blocker
- hydrochlorothiazide (HCTZ) – a diuretic
Professor Massimo Volpe, of the University of Rome, explained:
“These additional analyses further build understanding of how the adjunctive use of this triple combination therapy can benefit patients. Effective lowering of blood pressure is central to reducing cardiovascular risk in hypertension patients.
These data show that triple combination therapy delivers reliable blood pressure reduction across the spectrum of hypertension management.”
Professor Reinhold Kreutz, acting director of the Institute of Clinical Pharmacology and Toxicology in Berlin, presented the first analysis of a 10 week study.
The study found that more participants with moderate to severe hypertension achieved normal/high-normal blood pressure (BP) levels (120/80-
Written By Grace Rattue